Diffuse large B-cell lymphoma: open trials in China

• NCT06481826

  Glofitamab in Chinese Patients With R/R DLBCL

  Research · Peking Union Medical College Hospital

  Peking Union Medical College Hospital, Beijing

  Registry updated 2026-03-27

• NCT07493109

  Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP

  Trial Treatment · Phase 3 · Ou Bai, MD/PHD

  The First Bethune Hospital of Jilin University, Changchun

  Registry updated 2026-03-25

• NCT07493148

  Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL

  Trial Treatment · Phase 2 · Ou Bai, MD/PHD

  The First Bethune Hospital of Jilin University, Changchun

  Registry updated 2026-03-25

• NCT05514327

  A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL

  Trial Treatment · Peking Union Medical College Hospital

  Peking Union Medical College Hospital, Beijing

  Registry updated 2026-03-24

• NCT07489989

  Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.

  Trial Treatment · Phase 2 · Daihong Liu

  Chinese PLA General Hospital, Beijing

  Registry updated 2026-03-24

• NCT07472621

  Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma

  Research · Henan Cancer Hospital

  Henan Cancer Hospital, Zhengzhou

  Registry updated 2026-03-16

• NCT06517511

  Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)

  Trial Treatment · Phase 2 · Sun Yat-sen University

  Sun Yat-sen University Cancer Center, Guangzhou · Fudan University Shanghai Cancer Center, Shanghai

  Registry updated 2026-02-12

• NCT07398638

  Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study

  Trial Treatment · Phase 1/2 · Sun Yat-sen University

  Sun Yat-sen University Cancer Center, Guangzhou

  Registry updated 2026-02-10

• NCT06829771

  Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma

  Trial Treatment · Phase 1/2 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

  Beijing Cancer Hospital, Beijing · The First Affiliated Hospital of Bengbu Medical College, Bengbu · The First Hospital of Jilin University, Changchun · The second Hospital of dalian, Dalian · Fujian Cancer Hospital, Fuzhou · Sun Yat-sen University Cancer Center, Guangzhou · Harbin Medical University Cancer Hospital, Harbin · Affiliated Cancer Hospital of Shandong First Medical University, Jinan · Gansu Provincial Cancer Hospital, Lanzhou · Liuzhou People's Hospital, Liuzhou · The Affiliated Hospital of Southwest Medical University, Luzhou · Maanshan People's Hospital, Ma’anshan · Jiangxi Canser Hospital, Nanchang · Jiangsu Provincial People's Hospital, Nanjing · Puyang Oilfield General Hospital, Puyang · The Second Affiliated Hospital of Fujian Medical University, Quanzhou · Fudan University Shanghai Cancer Center, Shanghai · Shanxi Cancer hospital, Taiyuan · People's Hospital of Tianjin (City), Tianjin · Tianjin Medical University Cancer Hospital, Tianjin · Hubei Cancer Hospital, Wuhan · The First Affiliated Hospital of Xi'an Jiao Tong University, Xi’an · The affiliated hospital of xuzhou medical university, Xuzhou · Yantai Yuhuangding Hospital, Yantai · Henan Cancer Hospital,Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou

  Registry updated 2026-01-30

• NCT07368270

  Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma

  Trial Treatment · Phase 1 · Jiangsu Topcel-KH Pharmaceutical Co., Ltd.

  Suzhou Hongci Hematology Hospital, Suzhou

  Registry updated 2026-01-28

• NCT07371923

  Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma

  Trial Treatment · Phase 2 · Beijing Tongren Hospital

  Beijing Tongren Hospital, Beijing

  Registry updated 2026-01-28

• NCT07348575

  A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma

  Trial Treatment · Phase 3 · Second Affiliated Hospital of Nanchang University

  The Second Affiliated Hospital of Nanchang University, Nanchang

  Registry updated 2026-01-16

• NCT07189065

  A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma

  Trial Treatment · Phase 2 · Guangzhou Lupeng Pharmaceutical Company LTD.

  Beijing Tongren Hospital, Beijing · National Cancer Center/Chinese Academy of Medical Sciences, Beijing · Beijing Shijitan Hospital, Beijing · Peking University Third Hospital, Beijing · The Second Xiangya Hospital of Central South University, Changsha · Hunan Cancer Hospital, Changsha · Sichuan Cancer Hospital, Chengdu · The First Affiliated Hospital of Chongqing Medical University, Chongqing · The Second Affiliated Hospital of Dalian Medical University, Dalian · Fujian Cancer Hospital, Fuzhou · Nanfang Hospital, Guangzhou · Affiliated Cancer Hospital of Guangzhou Medical University, Guangzhou · Guangdong Provincial People's Hospital, Guangzhou · The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou · The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou · Zhejiang Cancer Hospital, Hangzhou · Anhui Cancer Hospital (West Branch of Anhui Provincial Hospital), Hefei · The First Hospital of Jilin University, Jilin City · LinYi Cancer Hospital, Linyi · The First Affiliated Hospital of Henan University of Science and Technology, Luoyang · Meizhou People's Hospital, Meizhou · Jiangxi Cancer Hospital, Nanchang · The First Affiliated Hospital of NanChang University, Nanchang · Jiangsu Cancer Hospital, Nanjing · Affiliated Tumor Hospital of Guangxi Medical University, Nanning · The First Affiliated Hospital of Guangxi Medical University, Nanning · Fudan University Shanghai Cancer Center, Shanghai · Liaoning Cancer Hospital, Shenyang · Shengjing Hospital Of China Medical University, Shenyang · The Fourth Hospital of Hebei Medical University, Shijiazhuang · The First Affiliated Hospital of Soochow University, Suzhou · Shanxi Province Cancer Hospital, Taiyuan · Shanxi Bethune Hospital, Taiyuan · Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin · Hubei Cancer Hospital, Wuhan · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan · The First Affiliated hospital of Xiamen University, Xiamen · The affiliated hospital of xuzhou medical university, Xuzhou · Henan Provincial People's Hospital, Zhengzhou · The First Affiliated Hospital of Zhengzhou University, Zhengzhou · Henan Cancer Hospital, Zhengzhou

  Registry updated 2025-12-16

• NCT06803693

  Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

  Trial Treatment · Phase 2 · Ruijin Hospital

  Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai

  Registry updated 2025-12-08

• NCT07255963

  Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL

  Trial Treatment · Phase 2 · The First Affiliated Hospital of Soochow University

  The First Affiliated Hospital of Soochow University, Suzhou

  Registry updated 2025-12-01

• NCT07084662

  Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma

  Trial Treatment · Phase 2/3 · Sun Yat-sen University

  Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University,, Guangzhou

  Registry updated 2025-11-26

• NCT07231250

  Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

  Trial Treatment · Phase 2 · Li Zhiming

  Sun Yat-sen University Cancer Center, Guangzhou

  Registry updated 2025-11-19

• NCT07188077

  Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma

  Research · Ting YANG

  The First Affiliated Hospital of Fujian Medical University, Fuzhou

  Registry updated 2025-11-18

• NCT07198230

  Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell Lymphoma

  Research · Ting YANG

  The First Affiliated Hospital of Fujian Medical University, Fuzhou

  Registry updated 2025-11-18

• NCT06925555

  Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS

  Trial Treatment · Phase 2 · The First Affiliated Hospital with Nanjing Medical University

  The First Affiliated Hospital with Nanjing Medical University, Nanjing

  Registry updated 2025-09-30

• NCT06120166

  Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research

  Trial Treatment · Early phase 1 · He Huang

  The first affiliated hospital of medical college of zhejiang university, Hangzhou

  Registry updated 2025-09-19

• NCT07011056

  A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma

  Trial Treatment · Phase 3 · Chengdu Zenitar Biomedical Technology Co., Ltd

  West China Hospital，Sichuan University, Chengdu

  Registry updated 2025-09-19

• NCT07168291

  Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma

  Trial Treatment · Early phase 1 · First Affiliated Hospital Xi'an Jiaotong University

  First Affiliated Hospital of Xi'an Jiaotong University, Xi'an

  Registry updated 2025-09-17

• NCT07159906

  Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

  Trial Treatment · Phase 1/2 · First Affiliated Hospital of Zhejiang University

  Department of Hematology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou

  Registry updated 2025-09-08

• NCT06886139

  A Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL.

  Trial Treatment · Phase 2 · Zhejiang Teruisi Pharmaceutical Inc.

  Chinese Academy of Medical Sciences Cancer Hospital, Beijing

  Registry updated 2025-08-22

All Diffuse large B-cell lymphoma trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error